Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Contract Logix Helps Biotech and Pharmaceutical Industries Accelerate Innovation and Commercialization


Contract Logix

Data-Driven Contract Management Software

The pharmaceutical industry is undergoing a rapid and dynamic transformation, and it needs business tools that can keep pace. Taking a data-driven approach to contract management is essential for success and that’s exactly what our solution provides.

Contract Logix, a leading provider of data-driven contract management software, today announced a new “out-of-the-box” configuration of its contract lifecycle management solution specifically designed to support the unique contract management requirements of pharmaceutical and biotechnology organizations. This no-code, pre-configured version of Contract Logix’s platform allows pharmaceutical and biotech companies to rapidly and digitally transform the way they manage buy-side and sell-side contracts, and helps optimize the performance of the entire pharmaceutical contract lifecycle.

Contract Logix has over a decade of experience working with pharmaceutical and biotechnology organizations to streamline and automate their contract processes, as well as satisfy intense regulatory compliance requirements. As digital transformation initiatives and contracting complexities have intensified in the sector over the past year, Contract Logix has seen tremendous usage growth within its customer base resulting in a 307% increase in the number of contracts its pharmaceutical and biotechnology customers manage with its software.

The pre-configured version of the product will help new pharmaceutical and biotech customers quickly and effectively digitize and modernize their contract management processes and achieve the business and contracting objectives necessary to be successful in today’s operating environment.

Key Facts:


  • Extensive clinical trials, evolving FDA regulations, new supply chain dynamics, increased M&A activity, and ensuring compliance without compromising speed were real business challenges facing the pharmaceutical industry before the COVID-19 pandemic hit. The volume of contracts and contract data generated by pharmaceutical organizations is staggering (one study found that the average CDA is over 4,000 pages long), and the rising cost of drug development all adds an extra level of complexity to pharmaceutical companies’ contract management processes. COVID-19 has upended the supply chain, and the race to a vaccine has shined a light on the unique complexities of the pharmaceutical industry.
  • Contract Logix’s industry-specific “no-code” product configuration is based on over a decade of experience working with pharmaceutical and biotechnology companies to help modernize their entire contract lifecycle management business process. It allows companies to centralize and digitize all contracts and contractual information to get complete visibility into contract types such as HCP, payer, CDA, drug applications, PBMs, R&D, and outsourcing agreements, and it integrates easily with other pharmaceutical business applications.
  • Contract Logix’s data-driven CLM solution also gives pharmaceutical and biotechnology organizations the ability to simply and efficiently accelerate the way they request, submit, assemble, negotiate, execute, and manage legal agreements with intelligent and automated features such as workflows to follow business rules, alerts for key dates and obligations, contract stage, status and line item tracking, and document revision and version control.
  • Pharmaceutical and biotechnology organizations are inherently data-centric and the Contract Logix platform allows them to identify opportunities to improve contract performance through the system’s data-driven and pharmaceutical-specific KPIs and insights such as product pricing over time with customizable reporting and real-time performance dashboards.
  • The platform also helps ensure and demonstrate regulatory and internal compliance with real-time audit trails, electronic signatures and a robust suite of security capabilities, role-based and feature-based permissions, and critical certifications including SOC 2 Type 2 and HIPAA.

Executive Comments:

  • “The pharmaceutical industry is undergoing a rapid and dynamic transformation, and it needs business tools that can keep pace. Whether it’s evaluating research and development, tracking rebates, building partnerships, protecting IP, or optimizing vendors, taking a data-driven approach to contract management is essential for success and that’s exactly what our solution provides.” – Tim Donaghy, CTO, Contract Logix
  • “To be truly competitive, profitable, and innovative, pharmaceutical companies need to digitally transform the way they manage legal agreements with a data-driven contract management solution. We have over a decade of experience helping these companies address challenging trends like rising costs, evolving supply chain dynamics, and policy and regulatory changes, and we truly believe that digital contract transformation is a key differentiator in helping our customers accelerate clinical trials, vaccines and drug approvals.” – Rick Ralston, CEO, Contract Logix

Additional Information:

About Contract Logix

Contract Logix is a longtime leader, innovator, and provider of intelligent and data-driven contract lifecycle management software. The company’s software empowers legal, administration, IT, procurement, finance, and sales professionals across dozens of industries to digitally draft, negotiate, approve, execute, and manage their contracts. Hundreds of brands have partnered with Contract Logix to automate and streamline their contracting processes while minimizing risk, increasing compliance, and driving profitability. For more information about Contract Logix, visit https://www.contractlogix.com and follow us on LinkedIn.

Share article on social media or email:

Promises Behavioral Health Announces the Addition of its New Treatment Center in College Station, Texas


Promises Behavioral Health announces addition of Promises Brazos Valley to its family of addiction and mental health treatment centers

Knowing we are entering 2021 with this opening on the horizon is not only exciting for us as an organization, but it also reiterates our mission to provide attainable, affordable and accessible mental health and substance use treatment with evidence-based clinical integrity.

Promises Behavioral Health announced today the exciting planned addition of Promises Brazos Valley, the newest member to the Promises Behavioral Health family of addiction and mental health treatment centers. Set to open in spring 2021, Promises Brazos Valley will expand the regional footprint to reach more clients including young adults and adolescents in the south central Texas area.

This year has proven difficult for the United States as the nation has struggled with COVID-19 and the repercussions that come with social distancing, isolation, and quarantining. As a result, the U.S. has seen a sharp rise in substance use disorders across the nation. Promises Behavioral Health is answering the call to treat this rising substance abuse population by adding Promises Brazos Valley in a location centralized between Austin and Houston. In the heart of the Brazos Valley in College Station, Texas, Promises Brazos Valley will reach local communities, including the local collegiate population, and provide a high quality resource for surrounding areas to find evidence-based, residential addiction treatment.

With an opening currently slated at the end of March 2021, this new treatment center will bring specific curricula tailored for adolescents and collegiate young adults and will be well-suited to help any client in need of detox. The center intends to accept VA and all major commercial insurance benefits to further align with the local community. The campus building occupies more than 50,000 square feet, which allows the various planned programming to have dedicated space so that each demographic population served can find health and healing with peers of a similar age. This generous space also allows for a full continuum of partial hospitalization and other outpatient programs. Adding the Promises Brazos Valley location helps Promises Behavioral Health, as a whole, carry out its mission of access to treatment – healing more people and reaching more communities as the nation recovers from the results of the pandemic.

“Knowing we are entering 2021 with this opening on the horizon is not only exciting for us as an organization, but it also reiterates our mission to provide attainable, affordable and accessible mental health and substance use treatment with evidence-based clinical integrity,” remarked Doug Ginn, Chief Operating Officer with Promises Behavioral Health. “We are stepping into the new year with a lot of hope for helping people heal across the nation.”

With this addition to the family of Promises facilities, recovery communities in the south central Texas region can now expect an added layer of support. With its evidence-based program models, Promises Brazos Valley will help a variety of clients, no matter their age or background, find the hope and healing they need.

About Promises Behavioral Health

Promises Behavioral Health is a family of behavioral health programs with regional brands such as The Right Step, The Ranch and Promises. The company currently operates facilities across Texas, Tennessee, Florida, Pennsylvania and Massachusetts. Promises offers comprehensive, innovative treatment for substance abuse, sexual addiction, trauma, eating disorders and other mental health disorders. Through its programs, the company is committed to delivering clinically sophisticated treatment that promotes permanent lifestyle change, not only for the patient but for the entire family network. For more information, please visit http://www.PromisesBehavioralHealth.com.

Share article on social media or email:

Single-Dose Radiation Therapy Can Counteract Serious Breast Cancer Treatment Compliance Issues During Pandemic


SINGLE-DOSE RADIATION THERAPY CAN COUNTERACT SERIOUS BREAST CANCER TREATMENT COMPLIANCE ISSUES DURING PANDEMIC

TARGIT-IORT long-term data demonstrates equivalent outcomes to traditional 6-week radiotherapy, significantly reducing COVID-19 risk to patients

According to recent studies, an increase in the COVID-19 positivity rate correlates to an increase in mortality from non-coronavirus-related diseases. This includes breast cancer, and researchers believe fear of contracting the virus compels patients to stay home instead of completing their post-lumpectomy radiotherapy regimens.

However, physicians at Mercy Medical Center are countering this trend with a procedure called Targeted Intraoperative Radiotherapy, or TARGIT-IORT using the Intrabeam® System from ZEISS. Mercy was the first hospital in Maryland to acquire the INTRABEAM® Radiotherapy System in 2012, and remains the only hospital in the state to offer patients the INTRABEAM system.

IORT is a single treatment which takes the place of external beam radiation therapy (EBRT) done at the time of the lumpectomy.

“Unlike external beam radiation therapy (EBRT) which requires up to 30 visits to the radiotherapist, TARGIT-IORT achieves the same clinical outcomes with one dose of targeted radiation delivered from inside the breast during surgery immediately following the removal of the tumor,” explained Neil B. Friedman, M.D., FACS, Director of The Hoffberger Breast Center at Mercy.

Not only does TARGIT-IORT mitigate the side effects normally associated with irradiating the entire breast multiple times, it may lessen or even eliminate unsafe additional outside trips during the pandemic.

“With IORT, patients experience less irritation of healthy breast tissue, minimized exposure to the chest cavity and underlying organs, and fewer skin reactions, such as redness, rashes, and irritation. And now, given COVID-19, risk to the patient is reduced by eliminating the need to make multiple visits to the hospital for radiation treatments,” said Maria C.E. Jacobs, M.D., Director of Radiation Oncology at Mercy.

Since March of 2020, overall deaths in the United States have increased 20% compared to predicted mortality rates, according to a study published last month in the Journal of the American Medical Association.1 Yet fully one third of these “excess deaths” are due to causes other than COVID-19, leading researchers to conclude that the coronavirus is impacting Americans’ decisions to seek medical care for other diseases, including cancer. The study found a direct correlation between COVID-19 surges in the spring and an increase in non-coronavirus-related deaths during the same period of time.

“One of the trends the researchers noted is that treatment compliance – for a variety of diseases – seemed to be disrupted at a rate proportional to the severity of the pandemic,” Dr. Friedman said. “If elevated coronavirus levels earlier this year caused patients to abandon their radiotherapy regimens, we have every reason to expect compliance challenges to drastically increase again during the anticipated ‘second wave’ this fall and winter.”

Two additional studies have demonstrated the importance for patients to adhere to their cancer treatment regimen while also taking precautions to minimize their exposure to both radiation and potential coronavirus infection. A study published last month in the American Cancer Society journal Cancer found an increase in fatal outcomes among patients hospitalized with COVID-19 who had also recently undergone traditional post-surgical radiation therapy.2 Unfortunately, a second study found that delaying or skipping radiotherapy is also not a viable option. Published this month in the BMJ, researchers saw a significant increase in mortality among patients who deferred breast cancer treatment by as little as four weeks.3 Single-dose TARGIT-IORT, however, may decrease or eliminate both of these issues.

EBRT vs. TARGIT-IORT

External beam radiation therapy (EBRT) involves treating the entire breast from the outside. Although the radiation therapy is directed to the breast rather than the surrounding tissues, the proximity of the heart, lungs and skin limit the dose of radiation that can be given at any one time. This leads to a prolonged treatment course of 3-6 weeks following surgery. The TARGIT-IORT treatment administers the radiation dose from inside the breast at the time of surgery, precisely where it is needed. This allows the radiation oncologist to deliver a much higher dose at one time, avoiding irradiation of vital adjacent organs such as the lungs and heart.

TARGIT-A TRIAL

The effectiveness of TARGIT was investigated in an international study called the TARGIT-A Trial, a clinical trial that compared partial breast single dose targeted intraoperative radiotherapy (TARGIT-IORT) to 3 to 6 weeks of post-operative whole breast radiotherapy among women undergoing lumpectomy for early stage invasive ductal breast cancer. The clinical trial demonstrated equal breast cancer recurrence rates and equal cancer survival rates among recipients of targeted IORT during lumpectomy compared to those receiving multiple weeks of whole breast radiation after lumpectomy. The paper was published August 19 in BMJ4.

With long term follow-up (median 8.6 years, maximum 18.9 years), the TARGIT-A Trial demonstrated no significant difference in the 5- year local recurrence rates and 8.6 year local recurrence-free survival rate, breast cancer survival rate, and overall survival rate. Women receiving targeted IORT had a significantly lower risk of dying from other causes (e.g., heart disease or other cancers).

To learn more about TARGIT-IORT, please visit the consumer education website http://www.targetbreastcancer.org.

Founded in 1874 by the Sisters of Mercy, Mercy Medical Center is a university-affiliated medical facility with a national reputation for women’s health care. For more information, visit Mercy online at http://www.mdmercy.com, MDMercyMedia on Facebook and Twitter, or call 1-800-M.D.-Mercy.

REFERENCES

1. “Excess Deaths from COVID-19 and Other Causes, March-July 2020,” JAMA: The Journal of the American Medical Association, October 12, 2020.

https://link.zixcentral.com/u/9e62a721/sP05Kqk56xGmYr5eC2wmKA?u=https%3A%2F%2Fjamanetwork.com%2Fjournals%2Fjama%2Ffullarticle%2F2771761

2. “Association between recent oncologic treatment and mortality among patients with carcinoma who are hospitalized with COVID‐19: A multicenter study”, Cancer, November 02, 2020.

https://link.zixcentral.com/u/2ec10c44/Fog6Kqk56xGmYr5eC2wmKA?u=https%3A%2F%2Facsjournals.onlinelibrary.wiley.com%2Fdoi%2F10.1002%2Fcncr.33240

3. “Mortality due to cancer treatment delay: systematic review and meta-analysis”, BMJ, November 04, 2020

https://www.bmj.com/content/371/bmj.m4087

4. “Long term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomized clinical trial”, BMJ, August 19, 2020

https://www.bmj.com/content/370/bmj.m2836

PolyU to confer Honorary Doctorates upon Three Distinguished Individuals


Dr LAM Tai-fai, Chairman of Council, PolyU, said, “We are very excited to welcome them as new members of the PolyU family. Their extraordinary accomplishments, as well as their selfless and outstanding contributions to society deserve our utmost respect.”

The Hong Kong Polytechnic University (PolyU) announced that the University will confer honorary doctorates upon three distinguished individuals in recognition of their outstanding achievements in the fields of finance, scientific research, education and public health as well as their remarkable contributions to society. The three recipients are (in alphabetical order of surname): Mrs Laura CHA, GBM, GBS, JP, Professor XU Ningsheng and Professor ZHONG Nanshan.

Mrs Laura Cha, Professor Xu Ningsheng and Professor Zhong Nanshan are eminent individuals who have made significant contributions to our society and Nation. PolyU looks forward to more in-depth communication and collaboration with them in taking the University towards new horizons in education and research for the benefit of society.

Mrs Laura Cha is the Chairman of Hong Kong Exchanges and Clearing Limited, Non-executive Chairman of The Hongkong and Shanghai Banking Corporation Limited and Director of the World Federation of Exchanges. She is also a Non-official Member of the Executive Council of the Hong Kong Special Administrative Region. Mrs Cha has extensive experience in the field of financial management and has made impactful contributions to the development of the financial services sector in both Hong Kong and Mainland China. Mrs Cha was the first non-Mainland resident to join the Central Government at vice-ministerial rank when she served as Vice Chairman of the China Securities Regulatory Commission from 2001 to 2004. She previously served as Chairman of the University Grants Committee (UGC), Chairman of the Financial Services Development Council, Deputy Chairman of the Securities and Futures Commission, and Chairman of the Advisory Committee on Corruption of the Independent Commission Against Corruption.

Professor Xu Ningsheng is President of Fudan University and former President of Sun Yat-sen University, China. He is a Member of the Chinese Academy of Sciences and Academician of the Academy of Sciences for the Developing World. Professor Xu has served as a Representative of the 12th and 13th National People’s Congress and is a Member of the 13th National Five-year Plan National Expert Committee. Professor Xu is Chair of the General Expert Committee for the National Nanotechnology Key Project. He is also a Member of the UGC and has served on numerous international science and technology steering committees. Over the years, he has made significant contributions to the development of the Nation, especially in the areas of education and research.

Professor Zhong Nanshan is Professor of Medicine at the Guangzhou Medical University, Director of the State Clinical Research Centre of Respiratory Disease, Member of WHO’s Technical Advisory Group on COVID-19 Preparedness and Response, and Academician of the Chinese Academy of Engineering. Professor Zhong has a long and distinguished career in medical and scientific research related to respiratory diseases. Renowned for his achievements in fighting epidemics, Professor Zhong has made enormous contributions in leading the Chinese medical team to combat SARS in 2003. He is also instrumental in stopping the spread of COVID-19 in the Mainland. He not only identified the potential severity of the epidemic when it first emerged and raised awareness about human-to-human transmission, but also compiled a diagnosis and treatment protocol that contributed to controlling the epidemic and containing the number of cases in China. Professor Zhong was awarded the Order of the Republic in recognition of his tremendous contribution to the Nation.

Dr LAM Tai-fai, Chairman of Council, PolyU, said, “I would like to extend my congratulations on behalf of the University to Mrs Laura Cha, Professor Xu Ningsheng and Professor Zhong Nanshan. We are very excited to welcome them as new members of the PolyU family. Their extraordinary accomplishments, as well as their selfless and outstanding contributions to society deserve our utmost respect. We look forward to working closely with them for the continued advancement of PolyU in Hong Kong and Mainland China, contributing to the future development of Hong Kong and our Nation.”

Professor Jin-Guang TENG, PolyU President, stated, “The three esteemed honorary doctorate recipients have outstanding achievements in their professional careers and have set an excellent example in contributing to the Nation’s development and in driving social progress. In pursuit of their success, they embody the same values expressed in PolyU’s motto of ‘to learn and to apply, for the benefit of mankind’. The year 2020 has been very difficult and the world will continue facing social, economic and health challenges moving forwards. The devotion of the recipients to improving people’s lives and helping society to progress is highly motivational, encouraging all of us at PolyU to face the challenges and strive for breakthroughs in nurturing talent, pushing forward the frontiers of knowledge and technology, as well as serving our society to foster a much better tomorrow.”

Share article on social media or email:

Preventive Dental Care and Hygiene Importance Underlined by Possible Link Between COVID-19 and Serious Oral Ailments, says Premier Care Dental Group


The dental clinics sees to the oral health needs of patients young and old at its Pasadena, California offices.

A November 16 article on HuffPost reports on a newly speculated link between COVID-19 infection and adverse long-term effects on oral health. Medical experts quoted in the article hypothesize that either vascular damage near patients’ teeth or the possibility that the virus replicates in the oral cavity could be to blame. However, the article also stresses that it’s too early to definitively say whether the link is causational or only coincidental as more evidence is required. Pasadena-based Premier Care Dental Group says that even if the link proves unfounded, it’s still important for patients to have preventive general dental care, such as regular exams and cleanings, and to exercise excellent dental hygiene because of well-established threats like tooth decay and gum disease.

Premier Care Dental Group says that if COVID-19 does cause long-term damage to blood vessels near the teeth and gums, surviving patients may begin to notice symptoms such as loose teeth. The dental group says that patients should visit a dentist at the onset of symptoms as early treatment may be able to reverse or at least halt the progression of developing ailments. In the meantime, patients who practice excellent dental hygiene are giving themselves the best chance of maintaining their oral health says the group.

Even if the relationship between the coronavirus and oral ailments is ultimately determined to be exaggerated or situational, Premier Care Dental Group says it’s still in the best interests of patients to brush and floss their teeth routinely because of dangers such as tooth decay or gum disease, which can lead to an increased risk of cardiovascular disease, are tangible and proven.

Premier Care Dental Group notes that brushing for two minutes approximately thirty minutes after every meal can prevent or limit harmful plaque and tartar buildup. Flossing can help people clean otherwise hard-to-reach spots in between teeth to further clear out debris and contaminants, the group notes.

Visiting a dentist for a biannual checkup is equally important, the group says, because a professional is likely to spot potential causes for concern before they begin exhibiting notable symptoms. Catching an ailment before it has time to cause pain, discomfort, and serious damage is the best way to not only avoid suffering, but it also lessens the financial burden that is required to treat advanced conditions.

Premier Care Dental Group says this doesn’t mean that patients who have ignored the initial warnings or neglected to visit a dentist for a checkup can’t do anything about their now-serious oral ailments. If the worst occurs, patients can always visit a dentist for relief.

Readers can learn more about Premier Care Dental Group by visiting their website at https://www.premiercaredentalgroup.com/ or by calling (626) 795-6855.

Share article on social media or email:

Purple Antimicrobial, Inc. Partners with Santa to Give Away Purple P-19 Soap Spray During Holidays


News Image

Purple P-19 Soap Spray is the only alcohol-free, non-toxic soap spray that is made-in-the-USA, U.S. lab tested and proven to kill COVID-19 with an FDA registered formulation.

Purple Antimicrobial, Inc., the leader in eco-friendly household cleaning products, is partnering with Santa this holiday season to donate Purple P-19 Soap Spray to communities in need of cleaning supplies.

Purple P-19 Soap Spray is the only alcohol-free, non-toxic soap spray that is made-in-the-USA, U.S. lab tested and proven to kill COVID-19 with an FDA registered formulation. As preparations have begun for gift deliveries this year, Santa has announced that Purple P-19 Soap Spray is the official soap of Santa and the North Pole. All North Pole personnel, elves and reindeer alike, at the workshop are using Purple P-19 Soap Spray to ensure a safe holiday season.

Understanding the importance of hygiene, Santa will be using Purple P-19 Soap Spray at every stop along his route. Santa said, “We must all remember to clean our hands even while making gift deliveries. I always carry a bottle of Purple P-19 Soap Spray on my sleigh with me to make sure my reindeers and I are clean.” Purple P-19 Soap Spray is safe around the whole family and pets.

“We are thrilled to partner with Santa and the North Pole this season,” said Sergei Baranoff, Operations Manager, Purple Antimicrobial, Inc. “We want to make sure everyone has access to cleaning supplies this holiday season. After all, ’tis the season to be jolly and give back.”

With gift deliveries underway, Santa and his elves have been reaching out to consumers on Twitter that have Tweeted about not being able to find cleaning supplies on shelves at their local retailers.

To learn more about Purple and its products visit https://p19clean.com.

About Purple

Founded in 2018, Purple Antimicrobial, Inc. is the leader of cleaning products that kill germs and bacteria without alcohol. Purple P-19 Soap Spray is U.S. lab tested and proven to kill COVID-19 with an FDA registered formulation free from alcohol, ammonia, fumes and toxic chemicals. The company’s other products include Purple Multi-Purpose Cleaner and Degreaser and Wipe. These products are manufactured without sulfates, triclosan, formaldehyde, parabens, phosphates, SLS, SLES, ethyl, petroleum-based ingredients, animal by-products, chlorine, alcohol, or dyes and known as an eco-friendly, non-toxic household cleaning agent. Purple uses science to eliminate chemicals from the formula while creating a cleaner that outperforms other cleaners.

Share article on social media or email:

BayMark Announces the Acquisition of Its First U.S.-Based Residential Treatment Facility


The field of addiction treatment offers more options to patients than at any time in history and we’re proud to be a part of innovating the treatment itself, as well as improving access to all those in need.

BayMark Health Services announced this week an exciting addition to their portfolio of Substance Use Disorder Services, Liberty Bay Recovery Center, a residential treatment facility in Portland, Maine. BayMark is well-known in the addiction treatment industry as the North American leader in Opioid Use Disorder treatment with more than 250 facilities across the continent providing a variety of treatment options including medication-assisted treatment, counseling and both inpatient and outpatient withdrawal management services.

That portfolio, until recently, included only one residential treatment facility in Bala, Ontario, Greenestone Muskoka. The addition of Liberty Bay is a gratifying one for the company whose mission to improve the lives of individuals with substance use disorders will be well-served by bringing both their clinical and administrative expertise into a new U.S. treatment space.

David K. White, Ph.D, Chief Executive Office of BayMark Health Services shares, “The field of addiction treatment offers more options to patients than at any time in history and we’re proud to be a part of innovating the treatment itself, as well as improving access to all those in need. Each patient is unique, and as BayMark expands our continuum of care, what we’re really expanding is our ability to help each of those patients find the type and level of care that is right for them on their path to recovery.”

Liberty Bay offers treatment for a variety of addictions including not only opioids, but also alcohol, cocaine, methamphetamine, prescription drugs and other substances. Multiple levels of care including residential, partial hospitalization and intensive outpatient treatment provide patients with step-down care that meets each patient where they are at in their journey. Patients at Liberty Bay receive a customized treatment plan that may include both group and individual counseling, family program work, addiction education, life skills classes, relapse prevention strategies and resources, and around-the-clock supervision and support.

“Providing the ability of a patient anywhere in this country to access professional, comprehensive and compassionate care for addiction is our number one goal”, shared Mike Saul, BayMark Division President. “As we move into the residential space I couldn’t be more pleased to be working with Liberty Bay. Their facility, staff and the care provided is top-notch, and the foundation of excellence in patient care is one that BayMark will work diligently to not only maintain, but enhance.”

In addition to Liberty Bay, BayMark operates two medication-assisted treatment facilities in Portland and Lewiston, ME offering methadone and Suboxone®, as well as counseling, for the treatment of Opioid Use Disorder.

Mertz Taggart, a leading mergers and acquisitions firm, represented Liberty Bay in this transaction.

For more information about Liberty Bay, visit: http://www.LibertyBayRecovery.com.

About BayMark Health Services:

BayMark Health Services provides medication-assisted treatment to 53,000+ patients in recovery from substance use disorder across the United States and Canada. Our outpatient programs deliver medically-supervised treatment, in a variety of modalities and settings, to meet the diverse needs of our patients who struggle with the use of opioids, alcohol and other prescription and illicit substances.

The BayMark continuum of patient-focused services includes: highly structured opioid treatment programs utilizing methadone or buprenorphine and outpatient buprenorphine treatment programs, both of which incorporate counseling as part of an individualized treatment plan for opioid use disorder. Additionally, ambulatory withdrawal management services with naltrexone therapy, and inpatient detoxification services are offered for a variety of substance use disorders.

Share article on social media or email:

Whistleblower Attorney Releases Guide to Reporting NY Healthcare Fraud & Claiming Rewards


There’s a lot at stake and you only get one shot in whistleblower cases. You want to make it count. That’s why I wrote the book; so people will know what they’re getting into and how best to proceed.

Steven T. Halperin, a New York, NY attorney who is a nationally recognized authority on whistleblower litigation, has launched an informative e-book detailing the process of exposing healthcare fraud and claiming a reward.

Entitled The Medicare Whistleblower – Ten Step Guide to Reporting Healthcare Fraud & Earning a Reward https://www.uswhistleblowerlawyer.com/medicare-whistleblower-book/, Halperin’s e-book, available as a free download, explains how workers in the healthcare industry can come forward anonymously, expose illegal activity that puts patients at risk or cheats Medicare, Medicaid, or TRICARE and claim what can be a sizeable reward.

Halperin, whose whistleblower law firm https://www.uswhistleblowerlawyer.com in New York City and allied firms has recovered more than $10 billion in recent years with whistleblower rewards in the hundreds of millions, explains the process succinctly, comprehensively, and in everyday language.

The problem of healthcare fraud is immense, and the government is helpless to address the issue without help from brave citizens who are willing to come forward. As Halperin explains, “The government recovered more than $3 billion in losses due to fraud 2019, and fully $2.6 billion of that was healthcare fraud targeting programs such as Medicare, Medicaid and TRICARE.”

A federal law, the False Claims Act, allows private citizens with knowledge of fraud to file lawsuits on behalf of the government and to share in the amounts recovered. “The rewards can be substantial,” Halperin says. “Anywhere from 15 to 30 percent of the government’s recovery.”

“Knowledge and timing are the keys,” Halperin notes. “A potential whistleblower must have unique knowledge of a fraud scheme and must be the first to report it.”

Common fraud schemes New York whistleblowers have exposed include:


  • Billing for services never performed
  • Ordering unnecessary tests and treatments to drive up patient costs
  • Unlawful referral to facilities where the referring provider has a proprietary interest
  • Promoting and prescribing medications for unapproved uses
  • Paying or accepting kickbacks for medications and diagnostic services
  • Billing for brand name drugs when generics have been provided

According to Halperin, “Many of the folks who come forward are pharmaceutical reps who are told to ‘Sell, Sell, Sell’ using unlawful and unscrupulous tactics. But the deadly and illegal kicker is when they’re told to sell drugs for unapproved uses, because now they’re putting vulnerable patients at risk.”

Healthcare fraud, which can also be reported by physicians, nurses, hospital billing professionals and others, also depletes programs designed to assist the elderly, poor, and members of our Armed Forces.

Whistleblowers need not fear coming forward. “Individuals file their Complaints under seal,” Halperin says, “so they are completely anonymous at the outset. And the law protects them from retaliation later.” However, to ensure those protections, and to enhance their chances of a successful case, potential whistleblowers should consult a knowledgeable attorney.

“There’s a lot at stake, and you only get one shot,” Halperin cautions. “You want to make it count. That’s why I wrote the book; so people will know what they’re getting into and how best to proceed.”

Based in Manhattan, HALPERIN BIKEL LLC is a qui tam (False Claims Act whistleblowers) law firm with decades of experience in state and federal qui tam cases. The firm concentrates on helping U.S. and international whistleblowers expose fraud and maximize their cash rewards. In addition to healthcare fraud, the firm manages cases related to government appropriations fraud, defense contractor fraud, and securities fraud.

Healthcare industry workers who wish to report fraud against the state or federal government can first speak to an experienced attorney at Halperin Bikel confidentially and at no cost at (929) 290-1266.

Media Inquiries: Halperin Bikel is represented by Elite Lawyer Management https://www.elitelawyermanagement.com

Share article on social media or email:

Mediaplanet and Olivia Newton-John Team Up to Support those Fighting Breast Cancer


News Image

Breast cancer is the second most common type of cancer among women in the United States after lung cancer

Mediaplanet today announces the launch of this December’s edition of “Breast Health.” This campaign advocates for increased funding for breast cancer research and better public education about risk factors and prevention, highlights innovations in treatment and aftercare, and elevates some of the leading voices among breast cancer “thrivers.”

Breast cancer is the second most common type of cancer among women in the United States after lung cancer, and while it has a high rate of survivorship when caught early, there are still barriers to care and early detection — including lack of public information, systemic inequities, and medical facility closures due to the pandemic. Fortunately, healthcare providers and researchers have made massive strides in just the past decade when it comes to our understanding of the disease, including risk factors such as genetic predisposition and innovations in treatment and after-care. And the work is ongoing.

The print publication’s cover story features Olivia Newton-John, pop culture icon and three-time breast cancer survivor. In an exclusive interview, Newton-John discusses her new foundation, which is focused on funding research of plant-based cancer therapies. “There are over 100,000 species of plants in the Amazon forest alone and they’ve only studied three percent of those for therapeutic value,” the Grease star stated. Newton-John explained that her own experience with cancer treatments inspired a desire for a science-backed therapy that felt more natural.

The print component of “Breast Health” is distributed within today’s edition of USA TODAY in

Atlanta, Boston, Chicago, Los Angeles, New York, Philadelphia, Baltimore, San Francisco, Washington DC, Cincinnati, North Carolina, South Carolina, Florida, Pittsburgh, Nashville and Houston with a circulation of approximately 200,000 copies and an estimated readership of 600,000. The digital component is distributed nationally through a vast social media strategy and across a network of top news sites and partner outlets. To explore the digital version of the campaign, visit: https://www.futureofpersonalhealth.com/campaign/breast-health/

This campaign was made possible with the support of Athenex Oncology, HairUWear, Immunomedics, Innersense Organic Beauty, Inspirata, Lifetime Entertainment, MD Anderson Cancer, Qiagen, Revitalash Cosmetics, Salon Services, TurningPoint Breast Cancer Rehabilitation, Olivia Newton-John, Stand Up to Cancer, Amy Robach, American College of Medical Genetics and Genomics, TNBC Foundation, Melissa Berry, HairToStay, American Society of Plastic Surgeons, American Society for Clinical Pathology, and the United States Lactation Consultant Association.

About Mediaplanet

Mediaplanet specializes in the creation of content marketing campaigns covering a variety of industries. We tell meaningful stories that educate our audience and position our clients as solution providers. Our unique ability to pair the right leaders with the right readers, through the right platforms, has made Mediaplanet a global content marketing powerhouse. Our award-winning stories have won the hearts of countless readers while serving as a valuable platform for brands and their missions. Just call us storytellers with a purpose. Please visit http://www.mediaplanet.com for more on who we are and what we do.

Press Contact:

Sloane Ackerman

Sloane.ackerman@mediaplanet.com

(646) 619-3803

Share article on social media or email:

Montreux Promotes Jessica Hou to Managing Director


News Image

Montreux Growth Partners, a healthcare growth capital firm, today announced the appointment of Jessica Hou as Managing Director. In this role, she will expand on her leadership in sourcing and leading growth-stage investments in the healthcare sector and in managing the broader Montreux portfolio.

Montreux is excited about this milestone as it looks towards raising its next healthcare growth capital fund with a focus on healthcare technology companies. 2020 has been a productive year for the firm. Recently, Montreux portfolio company Pulmonx priced an upsized IPO and has reached over $1.5 billion in market value. In November, Montreux announced its latest growth capital investment in FinPay, a leading healthcare fintech company focused on patient payments, a deal which Jessica helped source and lead.

Since Jessica joined Montreux in 2012, she has been actively involved with a number of Montreux’s growth-stage investments in healthcare. She currently serves as a board member or observer at Colorescience, FinPay, Crown Laboratories, and TigerConnect. She previously managed investments that led to successful exits for Montreux, including SI-BONE (IPO) and Tobira Therapeutics (acquired by Allergan for up to $1.7 billion).

“We are excited to announce Jessica’s promotion,” said Daniel K. Turner III, founder and Managing Director of Montreux. “Jessica has made significant contributions to Montreux and our portfolio companies, from initial investments to realized exits, and we look forward to her continued leadership and success with our firm.”

Prior to joining Montreux, Jessica was an investor at Quaker Partners, a healthcare investment firm with over $700 million under management. She started her career in the healthcare and life sciences practice of Navigant Consulting (now Guidehouse). She holds an M.B.A from Stanford Graduate School of Business and a B.A. in Human Biology and English from Stanford University.

About Montreux Growth Partners

Montreux is dedicated to making growth capital investments in category-leading companies with products, technologies, and services that are advancing health. Montreux has invested in more than 60 companies across multiple funds. Within healthcare IT, Montreux has built a strong track record with leading companies such as MINDBODY (IPO, acquired by Vista Equity Partners), Kareo, TigerConnect, and FinPay. For more information please visit the company’s website at http://www.mepvc.com.

Share article on social media or email: